Page 90 - Read Online

82. Huang CS, Liao JW, Hu ML. Lycopene inhibits experimental 96. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty
metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. acids inhibit hepatocellular carcinoma cell growth through blocking
J Nutr 2008;138:538-43. beta-catenin and cyclooxygenase-2. Mol Cancer Ther 2009;8:3046-55.
83. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. 97. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji
Vegetables and fruit intake and cancer mortality in the Hiroshima/ T, Takachi R, Tanaka Y, Mizokami M, Tsugane S; Japan Public
Nagasaki Life Span Study. Br J Cancer 2003;88:689-94. Health Center-Based Prospective Study Group. Consumption of
84. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain n-3 fatty acids and fish reduces risk of hepatocellular carcinoma.
amino acids as pharmacological nutrients in chronic liver disease. Gastroenterology 2012;142:1468-75.
Hepatology 2011;54:1063-70.
85. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, 98. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC,
Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Long- Byrne CD, Investigators WT. Design and rationale of the WELCOME
Term Survival Study G. Effects of oral branched-chain amino acid trial: a randomised, placebo controlled study to test the efficacy of
granules on event-free survival in patients with liver cirrhosis. Clin purified long chainomega-3 fatty acid treatment in non-alcoholic fatty
Gastroenterol Hepatol 2005;3:705-13. liver disease [corrected]. Contemp Clin Trials 2014;37:301-11.
86. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, 99. Kepekci RA, Polat S, Celik A, Bayat N, Saygideger SD. Protective
Rossi Fanelli F, Abbiati R, Italian BSG. Nutritional supplementation effect of Spirulina platensis enriched in phenolic compounds against
with branched-chain amino acids in advanced cirrhosis: a double- hepatotoxicity induced by CCl4. Food Chem 2013;141:1972-9.
blind, randomized trial. Gastroenterology 2003;124:1792-801. 100. Yakoot M, Salem A. Spirulina platensis versus silymarin in the
87. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato treatment of chronic hepatitis C virus infection. A pilot randomized,
M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Ohashi Y, comparative clinical trial. BMC Gastroenterol 2012;12:32.
Long-Term Survival Study G. Overweight and obesity increase the 101. Mazokopakis EE, Papadomanolaki MG, Fousteris AA, Kotsiris DA,
risk for liver cancer in patients with liver cirrhosis and long-term oral
supplementation with branched-chain amino acid granules inhibits Lampadakis IM, Ganotakis ES. The hepatoprotective and hypolipidemic
liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol effects of Spirulina (Arthrospira platensis) supplementation in a Cretan
Res 2006;35:204-14. population with non-alcoholic fatty liver disease: a prospective pilot
88. Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda study. Ann Gastroenterol 2014;27:387-94.
T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K. 102. Bresci G, Piccinocchi M, Banti S. The use of reduced glutathione in
Oral branched-chain amino acid granules reduce the incidence of alcoholic hepatopathy. Minerva Med 1991;82:753-5. (in Italian)
hepatocellular carcinoma and improve event-free survival in patients 103. Dalhoff K, Ranek L, Mantoni M, Poulsen HE. Glutathione treatment
with liver cirrhosis. Dig Dis 2011;29:326-32. of hepatocellular carcinoma. Liver 1992;12:341-3.
89. Tsuchiya K, Asahina Y, Izumi N. Long time oral supplementation 104. Chayanupatkul M, Liangpunsakul S. Alcoholic hepatitis: a
with branched-chain amino acids improves survival and decreases comprehensive review of pathogenesis and treatment. World J
recurrences in patients with hepatocellular carcinoma. Nihon Gastroenterol 2014;20:6279-86.
Shokakibyo Gakkai Zasshi 2008;105:808-16. (in Japanese) 105. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos
90. Ichikawa T, Naota T, Miyaaki H, Miuma S, Isomoto H, Takeshima Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello
F, Nakao K. Effect of an oral branched chain amino acid-enriched F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho
snack in cirrhotic patients with sleep disturbance. Hepatol Res
2010;40:971-8. FJ. Combination of N-acetylcysteine and metformin improves
91. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin histological steatosis and fibrosis in patients with non-alcoholic
efficacy against human hepatocellular carcinoma. Clin Cancer Res steatohepatitis. Hepatol Res 2008;38:159-65.
2005;11:8441-8. 106. Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the
92. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or treatment of chronic liver disease: a systematic review and meta-
hepatitis B or C virus liver diseases. Cochrane Database Syst Rev analysis. PLoS One 2015;10:e0122124.
2007;(4):CD003620. 107. Lin CC, Yin MC. B vitamins deficiency and decreased anti-oxidative
93. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, state in patients with liver cancer. Eur J Nutr 2007;46:293-9.
Wright EC, Sinha R, Everhart JE; HALT-C Trial Group. Silymarin 108. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma
use and liver disease progression in the hepatitis C antiviral long- and vitamin D: a review. J Gastroenterol Hepatol 2011;26:1597-603.
term treatment against cirrhosis trial. Aliment Pharmacol Ther 109. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK, Tang W. Chinese
2011;33:127-37.
94. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke herbal medicines as adjuvant treatment during chemo- or radio-
RL, Doo E, Meyers CM, Reddy KR, Silymarin in N, Group CHS. therapy for cancer. Biosci Trends 2010;4:297-307.
Effect of silymarin (milk thistle) on liver disease in patients with 110. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su
chronic hepatitis C unsuccessfully treated with interferon therapy: a T, Cheng YC. Phase I/II study of PHY906/capecitabine in advanced
randomized controlled trial. JAMA 2012;308:274-82. hepatocellular carcinoma. Anticancer Res 2009;29:4083-92.
95. Moroni M, Zanlorenzi L. Complete regression following sorafenib 111. Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese Medicines
in unresectable, locally advanced hepatocellular carcinoma. Future in the treatment of hepatocellular cancers: a systematic review and
Oncol 2013;9:1231-7. meta-analysis. J Exp Clin Cancer Res 2009;28:112.

Hepatoma Research | Volume 2 | March 9, 2016 61